Antleron's "living therapy factory" turns cells into personalised therapies
3D Systems has announced a collaboration with Belgian start-up Antleron to advance biomedical and “living therapy” engineering with 3D printing.
Antleron, which specialises in the development of regenerative products and personalised patient care, has setup an R&D facility in Leuven to support and validate its 3D bioprinting projects. The company’s “living therapy factory” brings together cells, biomaterials, biologics, and bioreactors with artificial intelligence and 3D Systems printers to turn cells into personalised care.
Starting with 3D Systems ProJet MJP 2500 and Figure 4 technology, the aim is to create a scalable digital factory built on modular, closed parametric processes. In one use case, Antleron plans to advance the way cells and tissues are grown to enable the transition from a static 2D to bioreactor-based 3D cell culture, which could open new possibilities in functional medical implants, vaccines, cell therapies and living tissue.
Jan Schrooten, Antleron CEO, said: "The vision of Antleron is to sustainably bring living therapies into the clinic. 3D printing is key to this endeavour, and we are eager to collaborate with 3D Systems and its experts. I look forward to the pioneering solutions we'll be able to achieve to elevate the efficacy of bioprinting and extend its biomedical application reach."
"3D Systems is excited about working with Antleron as they explore bioprinting, and especially their capability to develop end-to-end solutions utilising the 3D Systems' state of the art printing platforms and materials," said Chuck Hull, co-founder and chief technology officer, 3D Systems. "As we look to the future, bioprinting and regenerative medicine are large opportunities for 3D printing, and we look forward to expanding the role 3D Systems will play in these exciting fields."
Both companies will exhibit at Formnext on 19-22 November in Frankfurt.
